HomeInsightsStock Comparison

Concord Biotech Ltd vs Mankind Pharma Ltd Stock Comparison

Concord Biotech Ltd vs Mankind Pharma Ltd Stock Comparison

Last Updated on: Aug 05, 2025

Key Highlights

  • The Latest Trading Price of Concord Biotech Ltd is ₹ 1690 as of 05 Aug 12:58.
  • The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 0 on March 2025 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 50.2 on March 2025 . This represents a CAGR of 2.16% over 2 years.
  • The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 2 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 99973 crore on March 2025 . This represents a CAGR of 4.23% over 2 years.
  • The revenue of Concord Biotech Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 439.27 crore. This represent the decline of -100% The revenue of Mankind Pharma Ltd for the Jun '25 is ₹ 3653 crore as compare to the Mar '25 revenue of ₹ 3333 crore. This represent the growth of 9.61%.
  • The ebitda of Concord Biotech Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 198.26 crore. This represent the decline of -100% The ebitda of Mankind Pharma Ltd for the Jun '25 is ₹ 929.82 crore as compare to the Mar '25 ebitda of ₹ 932.5 crore. This represent the decline of -0.29%.
  • The net profit of Concord Biotech Ltd changed from ₹ 54.49 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 444.62 crore over 9 quarters. This represents a CAGR of -4.59% .
  • The Dividend Payout of Concord Biotech Ltd changed from 24.05 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Concord Biotech Ltd

  • Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
  • Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
  • Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

Concord Biotech Ltd News Hub

News

Concord Biotech to declare Quarterly Results

Concord Biotech will hold a meeting of the Board of Directors of the Company on 8 August 2...

Read more

04 Aug 2025 12:03

News

Concord Biotech's Dholka unit clears Russian GMP inspection

Concord Biotech announced the successful completion of the Russian GMP (Good Manufacturing...

Read more

26 Jul 2025 10:02

News

Concord Biotech acquires 75% stake in Stellon Biotech

Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This in...

Read more

02 Jul 2025 12:10

News

Concord Biotech edges higher on value buying; trades above 100-day SMA

The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its ...

Read more

25 Jun 2025 11:40

News

Concord Biotech's API facility completes USFDA inspection

Concord Biotech has received an Establishment Inspection Report (EIR) from the US Food and...

Read more

24 Jun 2025 19:06

News

Board of Concord Biotech recommends final dividend

Concord Biotech announced that the Board of Directors of the Company at its meeting held o...

Read more

30 May 2025 11:14

Mankind Pharma Ltd News Hub

News

Board of Mankind Pharma recommends Interim Dividend

Mankind Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

31 Jul 2025 17:41

News

Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 31 July 202...

Read more

15 Jul 2025 10:48

News

Mankind Pharma Ltd spurts 2.92%, gains for five straight sessions

Mankind Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 265...

Read more

14 Jul 2025 13:00

News

Mankind Pharma AGM scheduled

Mankind Pharma announced that the 34th Annual General Meeting(AGM) of the company will be ...

Read more

04 Jul 2025 16:31

News

Mankind Pharma allots 57,709 equity shares under ESOP

Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Comp...

Read more

10 Jun 2025 13:26

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

23 May 2025 13:35

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Concord Biotech Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Concord Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Concord Biotech Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Mankind Pharma Ltd?

Market cap of Concord Biotech Ltd is 17,787 Cr while Market cap of Mankind Pharma Ltd is 108,481 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Mankind Pharma Ltd?

The stock performance of Concord Biotech Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Mankind Pharma Ltd?

As of August 5, 2025, the Concord Biotech Ltd stock price is INR ₹1700.3. On the other hand, Mankind Pharma Ltd stock price is INR ₹2628.4.

How do dividend payouts of Concord Biotech Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions